Update on renal affection in obesity


Cite item

Full Text

Abstract

Pathogenesis, clinical forms and prognosis of obesity-associated nephropathy are discussed.

References

  1. Hoefle G., Saely C.H., Aczel S. et al. Impact of central and total obesity on vascular mortality in patients undergoing coronary angiography. Int. J. Obes. 2005; 29: 785 - 791
  2. Rea D.J., Heimbach J.K., Grande J.P. et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int. 2006; 70(9): 1636 - 1641
  3. Despres J.-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur. Heart J. 2006; 8 (Suppl. B): B4 - B12
  4. Iseki K., Ikemiya Y., Kinjo K. et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int. 2004; 65 (5): 1870 - 1876
  5. Gelber R.P., Kurth T., Kausz A.T. et al. Association between body mass index and CKD in apparently healthy men. Am. J. Kidney Dis. 2005; 46: 871 - 880
  6. Kougias P., Chai H., Lin P.H. et al. Adipocyte-derived cytokine resistin causes endothelial dysfunction of porcine coronary arteries. J. Vasc. Surg. 2005; 41: 691 - 698
  7. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. J.A.M.A. 2002; 287 (3): 356 - 359
  8. Сhen J., Muntner P., Hamm L. et al. The metabolic syndrome and chronic kidney disease in U.S. Adults. Ann. Intern. Med. 2004; 140: 167 - 174.
  9. Wang Y., Cheng Х. et al. Aassociation between obesity and kidney diseases: A systematic review and meta-analysis. Kidney Int., 2008; 73: 18 - 23
  10. Wolf G. Obesity and renal hemodynamics. Contrib Nephrol. 2006; 151: 184-202
  11. Сагинова Е.А., Федорова Е.Ю., Фомин В.В. и др. Формирование поражения почек у больных ожирением. Тер. архив 2006; 36-41
  12. Kasiske B.L., Crosson J.T. Renal disease in patients with massive obesity. Arch. Intern. Med. 1986; 146 (6): 1105 - 1109
  13. Praga M., Hernandez E., Morales E. Clinical features and long-term outcome of obesity- associated focal segmental glomerulosclerosis. Nephrol. Dial. Transplant 2001; 15: 1790 - 1798
  14. Kasiske B.L., Napier J. Glomerular sclerosis in patients with massive obesity. Am. J. Nephrol. 1985; 5 (1): 45 - 50
  15. Sasatomi Y., Tada M., Uesugi N. et al. Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiology. 2001; 69 (2): 113 - 118
  16. Rea D.J., Heimbach J.K., Grande J.P. et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int. 2006; 70(9): 1636 - 1641
  17. Orfila C., Lepert J.C., Modesto A. et al. IgA nephropathy complicating diabetic glomerulosclerosis. Nephron. 1998; 79(3):279-287
  18. Amore A., Roccatello D., Picciotto G., Emancipator S.N. Processing of IgA aggregates in a rat model of chronic liver disease. Clin Immunol Immunopathol. 1997; 84(2):107-114.
  19. Despres J.-P., Lemieux I., Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. B.M.J. 2001; 322: 716 - 720
  20. Hall J.E., Brands M.W., Henegar J.R. Mechanisms of hypertension and kidney disease in obesity. Ann. N. Y. Acad. Sci. 1999; 892: 91 - 107
  21. Wicek A., Kokot F., Chudek J., Adamczak M. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol. Dial. Transplant. 2002; 17:191 - 195
  22. Gunter W., Sheldon C., Han D.C. et al. Leptin and renal disease. Am. J. Kidney Dis. 2002; 39: 1 - 11
  23. Wolf G., Ziyadeh F.N. Leptin and renal fibrosis. Contrib. Nephrol. 2006; 151: 175 - 183
  24. Han D.C., Isono M., Chen S. et al. Leptin stimulates type I collagen production in db/db mesangial cells, glucose uptake and TGF-b type II receptor expression. Kidney Int. 2001; 59: 1315-1323
  25. Wolf G., Hamann A., Han D.C. et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int. 1999; 6(3): 860-872
  26. Stam F, van Guldener C, Becker A. et al. Endothelial dysfunction contributes to renal functionassociated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J. Am. Soc. Nephrol. 2006; 17: 537-545
  27. Quehenberger P., Exner M., Sunder-Plassmann R. et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ. Res. 2002; 90: 711 - 718
  28. Turner N.C., Morgan P.J., Haynes A.C. et al. Elevated renal endothelin-I clearance and mRNA levels associated with albuminuria and nephropathy in non-insulin-dependent diabetes mellitus: studies in obese fa/fa Zucker rats. Clin. Sci. (Lond). 1997; 93: 565 - 571
  29. Barton M., Carmona R., Morawietz H. et al. Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension. 2000; 35 (1 Pt. 2): 329 - 336
  30. Mather K.J., Lteif A., Steinberg H.O., Baron A.D. Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes. Diabetes. 2004; 53: 2060 - 2066
  31. Zoccali C. Asymmetric dimethylarginine (ADMA): a cardiovascular and renal risk factor on the move. J Hypertens. 2006; 24(4): 611-619
  32. Palm F., Onozato M.L., Luo Z., Wilcox C.S. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007; 293(6): H3227-H3245
  33. Masuda H., Goto M., Tamaoki S., Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol. 1999; 126(1): 211-218
  34. Valkonen V.P., Tuomainen T.P., Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med. 2005; 10 (Suppl 1):S45-S48
  35. Krzyzanowska K, Mittermayer F, Kopp HP et al. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab. 2004; 89(12): 6277-6281
  36. Ito A., Tsao P.S., Adimoolam S. et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999; 99(24): 3092-3095
  37. Caglar K., Yilmaz M.I., Sonmez A. et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 2006; 70(4): 781-787
  38. Fliser D., Kronenberg F., Kielstein J.T. et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005; 16(8): 2456-2461
  39. Nieuwdorp M., Meuwese M.C., Vink H. et al. The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol. 2005; 16(5): 507-511
  40. Rana J.S., Nieuwdorp M., Jukema J.W., Kastelein J.J. Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease. Diabetes Obes. Metab. 2007; 9(3):218-232
  41. Wang W. Change in properties of the glycocalyx affects the shear rate and stress distribution on endothelial cells. J Biomech. Eng. 2007; 129(3):324-329
  42. Goligorsky M.S. Clinical assessment of endothelial dysfunction: combine and rule. Curr Opin Nephrol Hypertens. 2006; 15(6):617-624
  43. Rubio-Gayosso I., Platts S.H., Duling B.R. Reactive oxygen species mediate modification of glycocalyx during ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2006; 290(6): H2247-H2256
  44. Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН 2003; 11: 50 - 55
  45. Yuyun M., Alder A.I., Wareham N.J. What is the evidence that microalbuminuria is a predictor of cardiovascular disease events. Curr. Opin. Nephrol. Hypertens. 2005; 14: 271 - 276
  46. Schiffrin E.L., Touyz R.M. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am. J. Physiol Heart Circ. Physiol. 2004;287: H435-H446
  47. Touyz R.M., Schiffrin E.L. Reactive oxygen species in vascular biology: implications in hypertension. Histochem. Cell Biol. 2004;122:339 -352.
  48. Vendrell J., Broch M., Vilarrasa N. et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes. Res. 2004; 12(6): 962 - 971
  49. Wu Y., Liu Z., Xiang Z. et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006; 147(1): 44 - 50
  50. Heimbach J.K., Taler S.J., Prieto M. et al. Obesity in living kidney donors: clinical characteristics and outcomes in the era of laparoscopic donor nephrectomy. Am. J. Transplant. 2005; 5(5): 1057-1064
  51. Pesavento T.E., Henry M.L., Falkenhain M.E. et al. Obese living kidney donors: short-term results and possible implications. Transplantation. 1999; 68(10): 1491 - 1496.
  52. Espinoza R., Gracida C., Cancino J., Ibarra A. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant. Proc. 2006; 38(3): 888-889
  53. Stevenson F.T., Wheeldon C.M., Gades M.D. et al. Hyperphagia as a mediator of renal disease initiation in obese Zucker rats. Obes. Res. 2001; 9(8): 492 - 499
  54. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005; 365: 1415 - 1428
  55. Uribarri J., Katherine R. Tuttle Advanced Glycation End Products and Nephrotoxicity of High-Protein Diets, Clin. J. Am. Soc. Nephrol. 2006; 1: 1293-1299
  56. Wadden T.A., Berkowitz R.I., Womble L.G. et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N. Engl. J. Med. 2005; 353: 2111 - 2120
  57. Barbaro D., Orsini P., Pallini S. et al. Obesity in transplant patients: case report showing interference of orlistat with absorbtion of cyclosporine and review of literature. Endocr. Pract. 2002; 8(2): 124 - 126
  58. Errasti P., Garcia I., Lavilla J. et al. Reduction in blood cyclosporine concentration by orlistat in two renal transplant patients. Transplant Proc. 2002; 34(1): 137 - 139
  59. Evans S., Michael R., Wells. H. et al. Drug interaction in a renal transplant patient: cyclosporine-Neoral and orlistat. Am. J. Kidney Dis. 2003; 41(2): 493 - 496
  60. Chagnac A., Weinstein T., Herman M. et al. The effects of weight loss on renal function in patients with severe obesity. J. Am. Soc. Nephrol. 2003; 14: 1480 - 1486.
  61. Sharma S.K., McCauley J., Cottam D. et al. Acute changes in renal function after laparoscopic gastric surgery for morbid obesity. Surg. Obes. Relat. Dis. 2006; 2(3): 389-392
  62. Parving H.H., Lenhert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 2001; 345: 870 - 878
  63. Praga M., Hernandez E., Morales E. et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol. Dial. Transplant. 2001; 16(9): 1790 - 1798
  64. Blanco S., Vaquero M., Gomez-Guerrero C. et al. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension. Am. J. Hypertens. 2005; 18 (4 Pt. 1): 557-565
  65. Adelman R.D., Restaino I.G., Alon U.S., Blowey D.L. Proteinuria and focal segmental glomerulosclerosis in severely obese adolescents. J. Pediatr. 2001; 138 (4): 481 - 485
  66. Kurata A., Nishizawa H., Kihara S. et al. Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. Kidney Int. 2006; 70(10): 1717-1724
  67. Parving H, Persson F., Lewis J. at al. Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. N.Engl.J.Med. 2008; 358(23):2433-2446
  68. Kielstein J.T., Fliser D. Lowering asymmetric dimethylarginine-a new mechanism mediating the renoprotective effects of renin-angiotensin system inhibitors in proteinuric patients? Blood Purif. 2007;25(4):324-6.
  69. Teplan V., Schück O., Racek J. et al. Reduction of plasma asymmetric dimethylarginine in obese patients with chronic kidney disease after three years of a low-protein diet supplemented with keto-amino acids: a randomized controlled trial. Wien Klin. Wochenschr. 2008; 120(15-16):478-485
  70. Nathan D.M. Thiazolidinediones for initial treatment of type 2 diabetes? N. Engl. J. Med. 2006; 355(23): 2477 - 2480

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies